Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?

BACKGROUND/HISTORICAL PERSPECTIVE: Availability of biologic disease-modifying antirheumatic drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also increased the cost of treatment. Biosimilars, the regulated copies of biologic products, have a potential to reduce health c...

Descripción completa

Detalles Bibliográficos
Autores principales: Azevedo, Valderilio Feijó, Babini, Alejandra, Caballero-Uribe, Carlo V., Castañeda-Hernández, Gilberto, Borlenghi, Cecilia, Jones, Heather E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392209/
https://www.ncbi.nlm.nih.gov/pubmed/30059414
http://dx.doi.org/10.1097/RHU.0000000000000881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392209/
https://www.ncbi.nlm.nih.gov/pubmed/30059414
http://dx.doi.org/10.1097/RHU.0000000000000881

Ejemplares similares